Clinical Lab Services2019-08-02T01:02:19+00:00
CLINICAL LAB SERVICES

Internationally Standardized Testing

CLINICAL LAB SERVICES

Internationally
Standardized Testing

LabPMM offers clinical services with global reach

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

LabPMM offers clinical services with global reach

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

NGS Cancer Panels

NGS Cancer Panels

Cytogenetic identification of chromosome abnormalities has become essential for the clinical management of patients with leukemia and is currently used to help categorize patients into risk groups.

Cytogenetic identification of chromosome abnormalities has become essential for the clinical management of patients with leukemia and is currently used to help categorize patients into risk groups.

MRD NGS Tests

MRD NGS Tests

LabPMM’s MRD tests are NGS-based assays that can be used to detect clonal gene rearrangements identified at diagnosis within virtually all of the antigen receptor loci for both B- and T-cells.

LabPMM’s MRD tests are NGS-based assays that can be used to detect clonal gene rearrangements identified at diagnosis within virtually all of the antigen receptor loci for both B- and T-cells.

Targeted Genes

Targeted Genes

FLT3 and NPM1 assays are offered to detect targeted mutations.

FLT3 and NPM1 assays are offered to detect targeted mutations.

Clonality NGS Tests

Clonality NGS Tests

The unique process of genetic rearrangements in the immunoglobulin (Ig) and T-cell receptor (TCR) gene loci during immune cell development and maturation generates a vast pool of genetically distinct cells.

The unique process of genetic rearrangements in the immunoglobulin (Ig) and T-cell receptor (TCR) gene loci during immune cell development and maturation generates a vast pool of genetically distinct cells.

Companion Diagnostic (CDx) Tests

Companion Diagnostic (CDx) Tests

The fms related tyrosine kinase 3 (FLT3) is one of the most commonly mutated genes in acute myeloid leukemia (AML), occurring in approximately 30% of patients at the time of diagnosis1. Although generally associated with normal cytogenetics where patients have standard risk of relapse, FLT3 mutations have also been identified in sub-groups of patients with chromosomal abnormalities that are associated with high risk of disease relapse2-3.

The fms related tyrosine kinase 3 (FLT3) is one of the most commonly mutated genes in acute myeloid leukemia (AML), occurring in approximately 30% of patients at the time of diagnosis1. Although generally associated with normal cytogenetics where patients have standard risk of relapse, FLT3 mutations have also been identified in sub-groups of patients with chromosomal abnormalities that are associated with high risk of disease relapse2-3.

Custom Assays

Custom Assays

In response to the FDA announcing its intention to dramatically expand its regulatory oversight of laboratory developed tests (LDTs), Invivoscribe is partnering with laboratories worldwide to help facilitate the conversion of LDTs into FDA-cleared assays, as we know the barriers to bringing new assays online are often the availability of resources and the cost of validation.

In response to the FDA announcing its intention to dramatically expand its regulatory oversight of laboratory developed tests (LDTs), Invivoscribe is partnering with laboratories worldwide to help facilitate the conversion of LDTs into FDA-cleared assays, as we know the barriers to bringing new assays online are often the availability of resources and the cost of validation.